Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Michael Werner

Urology Harrison, NY Medical Doctor

NPI 1124340294 CMS profile 366954

440 Mamaroneck Ave Ste 201, Ste 205, Harrison, NY 10528

Open in the dashboard

General payments

$10,705

342 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Michael Werner of Harrison, NY is reported in the CMS Open Payments database as having received $10,705 across 342 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 82nd percentile of Urology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $675 30
2024 General $553 20
2023 General $757 37
2022 General $5,607 68
2021 General $1,555 97
2020 General $840 53
2019 General $718 37

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Michael Werner
  • Urology median
  • Middle half of Urology
  • National median

In program year 2025, general payments to Michael Werner were reported at $675. Among 9,461 Urology profiles paid that year, the median was $629 and the middle half received between $190 and $1,620.

Show as a table
Year Michael Werner Urology median Middle half National median
2019 $718 $480 $147–$1,201 $163
2020 $840 $246 $87–$645 $114
2021 $1,555 $358 $111–$1,000 $132
2022 $5,607 $476 $143–$1,263 $149
2023 $757 $560 $168–$1,461 $160
2024 $553 $563 $170–$1,464 $164
2025 $675 $629 $190–$1,620 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Acerus Pharmaceuticals Corporation $4,590 11 payments
  2. AbbVie, Inc. $1,178 72 payments
  3. Bausch Health US, LLC $908 51 payments
  4. Endo Pharmaceuticals Inc. $752 50 payments
  5. Takeda Pharmaceuticals U.S.A., Inc. $627 35 payments
  6. ViiV Healthcare Company $540 26 payments
  7. Gilead Sciences, Inc. $439 22 payments
  8. Antares Pharma, Inc. $438 15 payments
  9. Endo USA, Inc. $314 10 payments
  10. Allergan Inc. $261 19 payments
  11. Other $660 31 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $6,477 337 payments
  2. Consulting Fee $3,850 1 payment
  3. Travel and Lodging $337 1 payment
  4. Debt forgiveness $27 1 payment
  5. Education $14 2 payments
Products named General payments · program years 2019–2025
  1. Natesto $4,590 11 payments
  2. VRAYLAR Neuroscience $1,107 64 payments
  3. XIAFLEX $1,066 60 payments
  4. APLENZIN $883 50 payments
  5. AVEED $804 52 payments
  6. EDEX $710 47 payments
  7. TRINTELLIX $507 25 payments
  8. APRETUDE $385 19 payments
  9. XYOSTED $217 3 payments
  10. VRAYLAR Neuroscience $203 15 payments
  11. Other $1,772 97 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 2 drugs

Part D claims

52

Median for Urology: 1,053

Drug cost

$1,943

Median for Urology: $101,464

Branded share of claims

38.5%

Median for Urology: 27.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Testosterone Cypionate Generic 32 $1,611
Bupropion Xl Bupropion Hcl Brand 20 $333

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 10,221 Part D prescribers listed as Urology; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 9 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
XIAFLEX
  • Endo USA, Inc. $229
  • Endo Pharmaceuticals Inc. $9
$239 — —
APRETUDE
  • ViiV Healthcare Company $69
$69 — —
JATENZO
  • TOLMAR, INC. $27
$27 — —
BOTOX
  • AbbVie, Inc. $23
$23 — —
APLENZIN
  • Bausch Health US, LLC $23
$23 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 9 in the dashboard with a free account

Records

342 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Urology in New York

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record